tacrolimus and Paraparesis--Tropical-Spastic

tacrolimus has been researched along with Paraparesis--Tropical-Spastic* in 2 studies

Other Studies

2 other study(ies) available for tacrolimus and Paraparesis--Tropical-Spastic

Article	Year
Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:5 This report describes a patient who developed human T-cell leukemia virus type I-associated myelopathy (HAM) following a living-donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T-cell leukemia virus type I (HTLV-I) carriers. Since the LDLT, he had been treated with immunosuppressive drugs such as tacrolimus and steroids as well as interferon-alpha to prevent rejection and a recurrence of the HCV infection, respectively. Even though the HTLV-I proviral load had decreased upon interferon treatment, he developed a slowly progressive gait disturbance with urinary disturbance 2 years after the LDLT and was diagnosed with HAM. This appears to be the first report of HAM development in an HLTV-I-infected LDLT recipient. Topics: Antiviral Agents; Drug Therapy, Combination; Gait Disorders, Neurologic; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Paraparesis, Tropical Spastic; Recombinant Proteins; Steroids; Tacrolimus; Treatment Outcome; Urination Disorders	2008
FK506 and cyclosporin a regulate proliferation and proto-oncogene expression in HTLV-1-associated myelopathy/tropical-spastic-paraparesis-derived T cells. International journal of cancer, 1993, May-08, Volume: 54, Issue:2 Human T-cell-leukemia-virus-type-1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP). The T-cell-targeting immunosuppressants, FK506 and cyclosporin A (CsA), suppressed proliferation of the HAM/TSP-derived T-cell lines, H89-59, H89-79 and H109. FK506 and CsA also reduced expression of the proto-oncogenes, c-myc and c-fos, but not c-jun and interleukin-2-receptor-alpha (IL-2R alpha) gene in H109 cells. The growth-inhibitory effects of FK506 and CsA were not abrogated by interleukin 2 (IL-2). These results suggest that the inhibitory effects of FK506 and CsA are independent of IL-2, and are associated with the reduction of c-myc and c-fos gene expression. Topics: Cell Division; Cycloheximide; Cyclosporine; Gene Expression; Genes, fos; Genes, jun; Genes, myc; Humans; Interleukin-2; Paraparesis, Tropical Spastic; Proto-Oncogene Mas; Proto-Oncogenes; Receptors, Interleukin-2; RNA, Messenger; T-Lymphocytes; Tacrolimus	1993

Article

Year

Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:5

This report describes a patient who developed human T-cell leukemia virus type I-associated myelopathy (HAM) following a living-donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T-cell leukemia virus type I (HTLV-I) carriers. Since the LDLT, he had been treated with immunosuppressive drugs such as tacrolimus and steroids as well as interferon-alpha to prevent rejection and a recurrence of the HCV infection, respectively. Even though the HTLV-I proviral load had decreased upon interferon treatment, he developed a slowly progressive gait disturbance with urinary disturbance 2 years after the LDLT and was diagnosed with HAM. This appears to be the first report of HAM development in an HLTV-I-infected LDLT recipient.

Topics: Antiviral Agents; Drug Therapy, Combination; Gait Disorders, Neurologic; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Paraparesis, Tropical Spastic; Recombinant Proteins; Steroids; Tacrolimus; Treatment Outcome; Urination Disorders

2008

FK506 and cyclosporin a regulate proliferation and proto-oncogene expression in HTLV-1-associated myelopathy/tropical-spastic-paraparesis-derived T cells.

International journal of cancer, 1993, May-08, Volume: 54, Issue:2

Human T-cell-leukemia-virus-type-1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP). The T-cell-targeting immunosuppressants, FK506 and cyclosporin A (CsA), suppressed proliferation of the HAM/TSP-derived T-cell lines, H89-59, H89-79 and H109. FK506 and CsA also reduced expression of the proto-oncogenes, c-myc and c-fos, but not c-jun and interleukin-2-receptor-alpha (IL-2R alpha) gene in H109 cells. The growth-inhibitory effects of FK506 and CsA were not abrogated by interleukin 2 (IL-2). These results suggest that the inhibitory effects of FK506 and CsA are independent of IL-2, and are associated with the reduction of c-myc and c-fos gene expression.

Topics: Cell Division; Cycloheximide; Cyclosporine; Gene Expression; Genes, fos; Genes, jun; Genes, myc; Humans; Interleukin-2; Paraparesis, Tropical Spastic; Proto-Oncogene Mas; Proto-Oncogenes; Receptors, Interleukin-2; RNA, Messenger; T-Lymphocytes; Tacrolimus

1993